The American Journal of Psychiatry requires its editors to disclose any financial relationships with commercial interests, including consulting with pharmaceutical companies or receiving honoraria from them. These relationships were as follows:
Robert Freedman, M.D., reports no financial relationships with commercial interests.
David A. Lewis, M.D., currently receives investigator-initiated research support from Bristol-Myers Squibb and Pfizer, attended a scientific meeting for which his travel and lodging expenses were paid by Sanofi, and in 2011–2013 served as a consultant in the areas of target identification and validation and new compound development to Bristol-Myers Squibb and Concert Pharmaceuticals.
Robert Michels, M.D., reports no financial relationships with commercial interests.
Daniel S. Pine, M.D., reports no financial relationships with commercial interests.
Susan K. Schultz, M.D., has received research support from the Alzheimer’s Disease Cooperative Study for projects conducted in partnership with Baxter Healthcare and in partnership with Eli Lilly and Company.
Carol A. Tamminga, M.D., has served on a drug development advisory board for Intracellular Therapies; served as an expert witness for Kaye Scholer LLP; and has served as a consultant for Astellas, Eli Lilly, Lundbeck, and Puretech Ventures/Karuna.